Published in Chest on June 01, 1997
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
Regional lymph node classification for lung cancer staging. Chest (1997) 5.13
Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. Chest (1997) 4.10
Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med (1997) 3.29
Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Chest (1997) 2.91
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
A new immunodeficiency disorder in humans involving NK cells. Nature (1980) 1.78
Approach to the solitary pulmonary nodule. Mayo Clin Proc (1993) 1.51
An integrated approach to evaluation of the solitary pulmonary nodule. Mayo Clin Proc (1990) 1.47
Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med (1980) 1.41
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. J Natl Cancer Inst (1990) 1.37
The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur Respir J (2002) 1.33
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res (1996) 1.29
The value of bronchoscopy in the diagnosis of mycobacterial disease. A five-year experience. Chest (1981) 1.25
Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest (2001) 1.21
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol (1994) 1.18
Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol (1980) 1.17
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol (2005) 1.15
Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol (1999) 1.10
The flow-volume loop and main-stem bronchial obstruction. Am Rev Respir Dis (1988) 1.02
Acquired immunodeficiency syndrome associated with blood-product transfusions. Ann Intern Med (1983) 0.99
Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol (1994) 0.98
Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer (1986) 0.97
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol (1999) 0.96
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol (1999) 0.95
Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol (1989) 0.94
Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol (1994) 0.91
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol (1996) 0.91
Lung cancer: current concepts and prospects. CA Cancer J Clin (1983) 0.89
Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. Chest (1986) 0.87
Pulmonary resection of metastatic renal cell carcinoma. Chest (1983) 0.87
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer (1992) 0.85
In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemother Pharmacol (1987) 0.84
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res (1998) 0.84
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer (2000) 0.83
Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer. Am J Clin Oncol (1996) 0.82
Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol (1994) 0.82
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res (2001) 0.81
Preoperative evaluation of pulmonary risk factors. J Gen Intern Med (1988) 0.80
Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. Jpn J Clin Oncol (1987) 0.80
Benzo(a)pyrene metabolism and blast transformation in peripheral blood mononuclear cells from smoking and nonsmoking populations and lung cancer patients. Cancer (1978) 0.80
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP. Am J Clin Oncol (1986) 0.79
Treatment toxicities in long-term survivors of limited small cell lung cancer. Cancer Invest (1988) 0.79
Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol (1998) 0.79
p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics (1998) 0.79
Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol (1999) 0.79
Chemotherapy for malignant mesothelioma; CAMEO. Am J Clin Oncol (1982) 0.78
New agents in the treatment of small cell lung cancer. Chest (1998) 0.78
Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J Biol Response Mod (1985) 0.78
Chemotherapy for advanced lung cancer. When to expect a response. Postgrad Med (1997) 0.77
Impaired generation of helper T cells in a patient with chronic mucocutaneous candidiasis and malignant thymoma. J Clin Lab Immunol (1983) 0.77
Clinical strategies for solitary pulmonary nodule. Annu Rev Med (1992) 0.76
A prospective study of pulmonary function in patients receiving mitomycin. Chest (1996) 0.76
Variation of microsomal mixed function oxidase(s) and human lung cancer. Cancer (1980) 0.76
Malignant pleural mesothelioma. A proposed new staging system. Chest (1995) 0.76
Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung. Am J Clin Oncol (1996) 0.76
A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer. J Clin Oncol (1988) 0.76
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol (1986) 0.76
Macromolecular binding of 3H-benzo(a)pyrene metabolites and lymphocyte transformation in patients with lung cancer, and in smoking and nonsmoking control subjects. Am Rev Respir Dis (1979) 0.75
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol (2004) 0.75
Stage II (T3) lung cancer. Chest Surg Clin N Am (2001) 0.75
A phase I-II study of sequential infusion VP-16 and cisplatin therapy in advanced lung cancer. Am J Clin Oncol (1989) 0.75
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. J Clin Oncol (1985) 0.75
Treatment of non-small-cell lung cancer. Compr Ther (1996) 0.75
Non-Hodgkin's lymphoma presenting as Pancoast's syndrome. Respir Med (1997) 0.75
Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. 1986. Chest (2009) 0.75
Lung cancer: the American view. Eur Respir J (1989) 0.75
Spiral computed tomography screening for lung cancer is ready for prime time. Am J Respir Crit Care Med (2001) 0.75
Magnetic resonance imaging of the chest: a diagnostic comparison with computed tomography and hilar tomography. Magn Reson Imaging (1984) 0.75
Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma. Jpn J Cancer Res (1986) 0.75
Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. J Natl Cancer Inst (1993) 0.75
Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer. Am J Clin Oncol (1989) 0.75
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer (1993) 0.75
Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys (1989) 0.75
Phase II trial of edatrexate in small cell lung cancer. Cancer (1994) 0.75
Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst (1993) 0.75
Aryl hydrocarbon hydroxylase activity in subpopulations of peripheral blood mononuclear cells. Cancer Res (1978) 0.75
Body plethysmography in the evaluation of intrathoracic airway abnormalities. Chest (1992) 0.75
Effect of various immunoregulatory substances on the growth inhibitory activity (GIA) of human monocytes against lymphoblastoid cell lines. Immunopharmacology (1982) 0.75
Aryl hydrocarbon hydroxylase in man and lung cancer. Hum Genet Suppl (1978) 0.75